PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184321
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2184321
Peptide-Based Gastrointestinal Disorders Therapeutics Market is estimated to be valued at USD 5.79 Bn in 2026 and is expected to reach USD 9.80 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.79 Bn |
| Historical Data for: | 2020 to 2024 | Forecast Period: | 2026 to 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.80% | 2033 Value Projection: | USD 9.80 Bn |
The market is witnessing steady growth mainly driven by the increasing prevalence of gastrointestinal disorders, rising adoption of peptide-based therapies, and continued development and commercialization of targeted treatments for conditions such as irritable bowel syndrome with constipation (IBS-C), chronic constipation, and short bowel syndrome.
Peptide-based gastrointestinal therapeutics include peptide and peptide-analog medicines designed to regulate gastrointestinal function, improve intestinal absorption, and manage chronic gastrointestinal symptoms. Key therapies covered in the market include linaclotide, teduglutide, and plecanatide, which are administered through oral and injectable routes depending on the indication and treatment requirement.
The market is increasingly benefiting from indication expansion and broader patient access to established peptide therapies. In November 2025, the U.S. FDA approved linaclotide for pediatric patients aged seven years and older with IBS-C, while in May 2026, its functional constipation indication was expanded to children aged two years and older. Development of long-acting peptide analogs for severe gastrointestinal conditions such as short bowel syndrome with intestinal failure is also broadening the therapeutic scope of the market.
The market is witnessing strong momentum owing to the growing burden of irritable bowel syndrome, chronic idiopathic constipation, functional constipation, and short bowel syndrome, together with increasing adoption of peptide-based treatment approaches. A 2026 systematic review and meta-analysis across 44 countries estimated the pooled prevalence of functional constipation at 12.14%, highlighting a substantial potential treatment population.
Growth is also being supported by strong commercialization of established therapies such as linaclotide and plecanatide. Linaclotide is expected to account for approximately 61.5% of the market in 2026, supported by its established use across IBS-C, chronic idiopathic constipation, and pediatric functional constipation. The irritable bowel syndrome segment is projected to account for approximately 43.5% of the market in 2026, reflecting the substantial disease burden and availability of targeted peptide treatments.
The development of next-generation and long-acting peptide analogs is further strengthening the market outlook. Companies are increasingly evaluating peptide therapies that may reduce dependence on parenteral nutrition and improve intestinal absorption in patients with short bowel syndrome. In June 2026, Ironwood Pharmaceuticals commenced the Phase III STARS-2 trial of apraglutide, a once-weekly synthetic GLP-2 analog for short bowel syndrome with intestinal failure.
Expansion of pediatric indications, improved prescription access, established retail pharmacy infrastructure, and continued commercialization across major markets are also contributing to market development. However, factors such as the high treatment cost of branded peptide therapeutics and limited availability of peptide-based gastrointestinal therapies in emerging markets may restrict broader adoption.